Archives of Medical Research
Volume 41, Issue 4 , Pages 275-280, May 2010

NAT2 Polymorphism and Gastric Cancer Susceptibility: A Meta-analysis

  • Xu Zhong

      Affiliations

    • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    • ,
  • Cao Hui

      Affiliations

    • Department of Radiation Oncology, Chongqing Medical University, Chongqing, China
    • ,
  • Wu Xiao-Ling

      Affiliations

    • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    • Corresponding Author InformationAddress reprint requests to: Wu Xiao-Ling, #76 Linjiang Road, Chongqing 400010, PR China; Phone: +86 023 63693325; FAX: +86 023 63711527
    • ,
  • Li Yan

      Affiliations

    • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    • ,
  • Luo Na

      Affiliations

    • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

Received 12 April 2010; accepted 2 June 2010.

(ARCMED-D-10-00167)

Background and Aims

N-acetyltransferase 2 (NAT2) is a polymorphic enzyme that plays an important role in the metabolism of various potential carcinogens. NAT2 can be subdivided into rapid and slow acetylation phenotype according to the different genotypes. Studies investigating the association between NAT2 polymorphisms and gastric cancer risk in humans showed conflicting results. The aim of this study was to conduct a meta-analysis assessing the association of NAT2 acetylation phenotype with risk of gastric cancer.

Methods

Relevant studies were identified through a search of Embase, ISI Web of Knowledge, Medline and Chinese Biomedicine Database until January 2010. A meta-analysis was conducted to quantitatively summarize association of NAT2 acetylation phenotype with GC susceptibility.

Results

Thirteen studies were included in the present meta-analysis, which described a total of 2,391 gastric cancer cases and 3,237 controls. The combined ORs for NAT2 slow or rapid acetylator and gastric cancer risk were 1.05 (95% CI 0.810–1.35) and 0.96 (95% CI 0.74–1.23), respectively. When stratifying for race and Lauren's classification, results also showed no significant association in genotype distribution between gastric cancer and control.

Conclusions

No association is found between NAT2 acetylation status and gastric cancer risk in this meta-analysis.

Key Words: NAT2, Stomach neoplasms, Polymorphism, Genetic susceptibility, Meta-analysis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0188-4409(10)00143-8

doi:10.1016/j.arcmed.2010.06.001

Archives of Medical Research
Volume 41, Issue 4 , Pages 275-280, May 2010

Article Tools

* Image Usage & Resolution